Welcome to our dedicated page for Tenax Therapeutics news (Ticker: TENX), a resource for investors and traders seeking the latest updates and insights on Tenax Therapeutics stock.
News for Tenax Therapeutics, Inc. (TENX) centers on its progress as a Phase 3, development-stage pharmaceutical company focused on cardiopulmonary therapies. The company’s updates highlight the clinical and regulatory path of levosimendan, which it is developing for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a form of pulmonary hypertension for which Tenax states no product has been approved.
Investors following TENX news can expect regular coverage of clinical trial milestones, including enrollment updates, design details, and key analyses from the Phase 3 LEVEL and LEVEL‑2 studies of TNX‑103 (oral levosimendan) in PH-HFpEF. Press releases have described the blinded sample size re-estimation in LEVEL, the initiation of the global LEVEL‑2 study, and the company’s plans for an open-label extension study to provide continued access to TNX‑103 for trial participants.
Tenax news also includes intellectual property developments, such as the European Patent Office’s Intention to Grant a patent covering levosimendan and its active metabolites in PH-HFpEF, and Canadian patent progress for multiple levosimendan formulations and combinations with cardiovascular drugs. These items provide context on the company’s efforts to build long-term protection around its lead asset.
In addition, TENX news features financial results and corporate updates, reported through quarterly earnings press releases, as well as participation in healthcare and investor conferences and virtual KOL events focused on PH-HFpEF and levosimendan. For readers tracking the evolution of Tenax’s late-stage cardiopulmonary program, this news feed offers a consolidated view of trial progress, IP status, and corporate communications. Bookmark this page to follow ongoing disclosures related to TENX and its PH-HFpEF development strategy.
Tenax Therapeutics (NASDAQ:TENX) reported Q2 2025 financial results and provided updates on its Phase 3 clinical programs. The company's lead program, TNX-103 (oral levosimendan), is progressing in the Phase 3 LEVEL study for PH-HFpEF treatment, with enrollment completion of 230 patients expected in H1 2026.
Key financial metrics include cash position of $105.5 million as of June 30, 2025, expected to fund operations through 2027. Q2 2025 resulted in a net loss of $10.9 million, with R&D expenses of $6.1 million and G&A expenses of $5.7 million.
The company secured patent protection in Canada extending to 2040 and remains on track to initiate its second Phase 3 study, LEVEL-2, in 2025 with a global footprint across 15 additional countries.
Tenax Therapeutics (NASDAQ: TENX) reported its Q1 2025 financial results and provided updates on its Phase 3 clinical trials. The company expects to complete enrollment of 230 patients in its Phase 3 LEVEL study for TNX-103 in PH-HFpEF by year-end 2025, with topline data expected mid-2026. A second Phase 3 study, LEVEL-2, is planned to commence in 2025.
Financial highlights include: cash position of $111.4 million as of March 31, 2025, bolstered by a $25 million private placement in March 2025. Q1 2025 saw increased expenses with R&D costs at $5.7 million (up from $2.7M in Q1 2024) and G&A expenses at $5.7 million (up from $1.2M). Net loss widened to $10.4 million compared to $3.8M in Q1 2024. The company expects current cash to fund operations through 2027.
Tenax Therapeutics (NASDAQ: TENX), a Phase 3 development-stage pharmaceutical company focused on cardiopulmonary therapies, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The conference will be held virtually from April 7-10, 2025. The company's corporate presentation is scheduled for April 7, 2025, at 3:45 p.m. ET. Key participants include Chris Giordano (President & CEO), Dr. Stuart Rich (Chief Medical Officer), and Doug Randall (Chief Business Officer).
Both live and archived versions of the presentation will be available through the company's investor relations webpage.
Tenax Therapeutics (NASDAQ: TENX) reported its Q4 and full-year 2024 financial results, highlighting successful private placements totaling $125 million to support two registrational studies for TNX-103 in PH-HFpEF. The company ended 2024 with $94.9 million in cash, with funding now extended through 2027.
The Phase 3 LEVEL study has been expanded to enhance statistical power, with enrollment completion targeted for year-end 2025 and topline data expected mid-2026. A second Phase 3 study, LEVEL-2, is planned to commence in 2025.
Financial highlights include increased R&D expenses of $12.7 million for 2024 (vs $3.2 million in 2023) and G&A expenses of $6.8 million (vs $5.0 million in 2023). The company reported a net loss of $17.6 million for 2024, compared to $7.7 million in 2023.
Tenax Therapeutics (NASDAQ: TENX) has secured a $25 million private placement financing through an agreement with RTW Investments. The deal includes 378,346 shares of common stock and pre-funded warrants to purchase 3,760,726 shares at $6.04 per share and $6.03 per warrant respectively.
The pre-funded warrants have a $0.01 exercise price with no expiration date. The placement, expected to close on March 5, 2025, is led by Leerink Partners, with Guggenheim Securities and William Blair as joint placement agents.
The net proceeds will fund the company's ongoing and planned Phase 3 clinical trials, working capital, capital expenditures, and general corporate purposes. The securities are being offered under Section 4(a)(2) of the Securities Act and Regulation D, with Tenax agreeing to file a registration statement within 45 days for resale of the shares.
Tenax Therapeutics (NASDAQ: TENX) has announced significant expansions to its Phase 3 LEVEL program for TNX-103 (oral levosimendan) in treating PH-HFpEF. The FDA has approved two key developments:
1. An amendment to expand the ongoing LEVEL study from 152 to 230 patients, increasing statistical power to over 95%. The study is expected to complete enrollment by end of 2025 with topline data expected mid-2026.
2. Approval to initiate LEVEL-2, a second global Phase 3 study, starting in 2025.
Current blinded LEVEL data shows strong patient retention with >95% continuation rates across multiple metrics. The company's $100 million financing from August 2024 supports these expanded trials. The studies aim to provide sufficient data for regulatory submissions in the U.S. and other regions for TNX-103, which targets PH-HFpEF, a condition currently without approved treatments.
Tenax Therapeutics (TENX), a Phase 3 development-stage pharmaceutical company focused on cardiovascular and pulmonary diseases, has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. The event will take place in New York from February 5-6, 2025.
Company President & CEO Chris Giordano will participate in a fireside chat on February 5, 2025, at 3:00 pm ET. The presentation will be available via webcast, accessible through the company's investor relations webpage. Additionally, Tenax management will be conducting one-on-one investor meetings during the conference, which can be arranged through Guggenheim representatives.
Tenax Therapeutics (NASDAQ: TENX) has appointed Gillian Andor, MSc, as Vice President of Clinical Operations. Andor brings over 20 years of experience and will lead the company's Clinical Operations function, supporting the ongoing Phase 3 LEVEL study of oral levosimendan (TNX-103) for PH-HFpEF treatment.
Andor's track record includes successful roles at Noema Pharma as Interim Head of Clinical Development Operations and at Sage Therapeutics, where she led programs resulting in NDA approvals for Zulresso® and Zurzuvae®. At Ironwood Pharmaceuticals, she contributed to the NDA approval of Linzess®.
The company granted Andor an inducement equity award of 250,000 stock options at $6.44 per share, vesting over four years in equal annual installments.
Tenax Therapeutics (TENX) reported Q3 2024 financial results, highlighting a successful $100 million private placement with institutional healthcare investors. The company's cash position reached $98.3 million as of September 30, 2024, providing runway through 2027. R&D expenses increased to $3.1 million from $1.1 million year-over-year, while G&A expenses rose to $1.5 million from $1.1 million. Net loss widened to $4.0 million compared to $2.0 million in Q3 2023. The company continues to expand its Phase 3 LEVEL study with 52 investigative sites now initiated.
Tenax Therapeutics (Nasdaq: TENX) has announced its participation in the Guggenheim Healthcare Innovation Conference in Boston, scheduled for November 11-13, 2024. CEO Chris Giordano will present a company update and discuss the development of levosimendan in a fireside chat format on November 13, 2024, at 1:00 PM EST.
The presentation, which will be available via live webcast and archived recording, will showcase the company's progress in developing treatments for cardiovascular and pulmonary diseases with high unmet medical need. Investors can access the presentation through the company's investor relations webpage or the provided webcast link.